Switch to:

Beam Therapeutics COGS-to-Revenue

: 0.00 (As of Mar. 2020)
View and export this data going back to 2020. Start your Free Trial

Beam Therapeutics's Cost of Goods Sold for the three months ended in Mar. 2020 was $0.00 Mil. Its Revenue for the three months ended in Mar. 2020 was $0.01 Mil.

Beam Therapeutics's COGS to Revenue for the three months ended in Mar. 2020 was 0.00.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. Beam Therapeutics's Gross Margin % for the three months ended in Mar. 2020 was 100.00%.

Beam Therapeutics COGS-to-Revenue Historical Data

* All numbers are in millions except for per share data and ratio. All numbers are in their local exchange's currency.

* Premium members only.

Beam Therapeutics Annual Data
Dec17 Dec18 Dec19
COGS-to-Revenue 0.00 0.00 0.00

Beam Therapeutics Quarterly Data
Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20
COGS-to-Revenue Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Beam Therapeutics COGS-to-Revenue Calculation

Beam Therapeutics's COGS to Revenue for the fiscal year that ended in Dec. 2019 is calculated as

COGS to Revenue=Cost of Goods Sold / Revenue
=0 / 0.018
=0.00

Beam Therapeutics's COGS to Revenue for the quarter that ended in Mar. 2020 is calculated as

COGS to Revenue=Cost of Goods Sold / Revenue
=0 / 0.006
=0.00

* All numbers are in millions except for per share data and ratio. All numbers are in their local exchange's currency.

Beam Therapeutics  (NAS:BEAM) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

Beam Therapeutics's Gross Margin % for the three months ended in Mar. 2020 is calculated as:

Gross Margin %=1 - COGS to Revenue
=1 - Cost of Goods Sold / Revenue
=1 - 0 / 0.006
=100.00 %

* All numbers are in millions except for per share data and ratio. All numbers are in their local exchange's currency.

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.

Beam Therapeutics COGS-to-Revenue Related Terms

Beam Therapeutics COGS-to-Revenue Headlines

No Headline

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)